Hypoxia as a factor for ga accumulation in tumour cells

Nuclear Medicine Communications

Volumn 25, Issue 1, 2004, Pages 49-53

  Kinuya, S ^a   LI, X F ^a   Yokoyama, K ^a   Mori, H ^a   Shiba, K ^a   Watanabe, N ^a   Shuke, N ^a   Bunko, H ^a   Michigishi, T ^a   Tonami, N ^a  

^a KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

Author keywords

Ga scintigraphy; Hypoxia; Transferrin

Indexed keywords

GALLIUM CITRATE GA 67; NITROGEN; TRANSFERRIN RECEPTOR; CITRIC ACID; DIAGNOSTIC AGENT; GALLIUM; GALLIUM CITRATE; RADIOPHARMACEUTICAL AGENT; TRANSFERRIN;

ANIMAL CELL; ARTICLE; BIOACCUMULATION; COLON CANCER; COMPLEX FORMATION; CONTROLLED STUDY; DRUG UPTAKE; HUMAN; HUMAN CELL; HYPOXIA; IN VITRO STUDY; INCUBATION TIME; MELANOMA CELL; MOUSE; NONHUMAN; RADIOACTIVITY; SCINTIGRAPHY; TUMOR CELL; ADENOCARCINOMA; ANIMAL; CELL HYPOXIA; COLON TUMOR; COMPARATIVE STUDY; EXPERIMENTAL MELANOMA; METABOLIC CLEARANCE RATE; METABOLISM; SCINTISCANNING; TUMOR CELL LINE;

ADENOCARCINOMA; ANIMALS; CELL HYPOXIA; CELL LINE, TUMOR; CITRATES; COLONIC NEOPLASMS; GALLIUM; HUMANS; MELANOMA, EXPERIMENTAL; METABOLIC CLEARANCE RATE; MICE; RADIOPHARMACEUTICALS; TRANSFERRIN;

EID: 4444346899     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/00006231-200401000-00007     Document Type: Article

References (38)

1. Bar-Shalom R, Mor M, Yefremov N, Goldsmith SJ. The value of Ga-67 scintigraphy and F-18 fluorodeoxyglucose positron emission tomography in staging and monitoring the response of lymphoma to treatment. Semin Nucl Med 2001; 31: 177-190.
2. Coiffier B. Positron emission tomography and gallium metabolic imaging in lymphoma. Curr Oncol Rep 2001; 3: 266-270.
3. 67Ga SPET. Eur J Nucl Med 2002; 29: 506-515.
4. Kostakoglu L, Goldsmith SJ. Positron emission tomography in lymphoma: comparison with computed tomography and gallium-67 single photon emission computed tomography. Clin Lymphoma 2000; 1: 67-74.
5. Kostakoglu L, Leonard JP, Kuji I, Coleman M, Vallabhajosula S, Goldsmith SJ. Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphoma. Cancer 2002; 94: 879-888.
6. Ojha B, Bender LW, Francisco R, Scott JW. Recurrent lymphoma detected on F-18 FDG coincidence imaging with negative findings on Ga-67 citrate scintigraphy. Clin Nucl Med 2002; 27: 638-640.
7. Rini JN, Manalili EY, Hoffman MA, Karayalcin G, Mehrotra B, Tomas MB, et al. F-18 FDG versus Ga-67 for detecting splenic involvement in Hodgkin's disease. Clin Nucl Med 2002; 27: 572-577.
8. 18F-fluoro-2-deoxyglucose positron emission tomography and gallium-67 citrate scintigraphy for detecting malignant lymphoma. Oncol Rep 2002; 9: 321-325.
9. 67Ga scintigraphy for restaging and treatment follow-up of lymphoma patients. Nucl Med Commun 2002; 23: 1079-1083.
10. Chajari M, Lacroix J, Peny A-M, Chesnay E, Batalla A, Henry-Amar M, et al. Gallium-scintigraphy in lymphoma: is there a benefit of image fusion with computed tomography? Eur J Nucl Med 2002; 29: 380-387.
11. 59Fe uptake by cultured mouse myeloma cells. Cancer Res 1977; 37: 3634-3638.
12. Larson SM, Rasey JS, Allen DR, Nelson NJ. A transferrin-mediated uptake of gallium-67 by EMT-6 sarcoma. 1. Studies in tissue culture. J Nucl Med 1979; 20: 837-842.
13. Wong H, Terner UK, English D, Noujaim AA, Lentle BC, Hill AR. The role of transferrin in the in vivo uptake of gallium-67 in a canine tumor. Int J Nucl Med Biol 1980; 7: 9-16.
14. Chitamba CR, Zivkovic Z. Uptake of gallium-67 by human leukemia cells: demonstration of transferrin receptor-dependent and transferrin-independent mechanisms. Cancer Res 1987; 47: 3929-3934.
15. Luttrop CA, Jackson JA, Jones BJ, Sohn M-H, Lynch RE, Morton KA. Uptake of gallium-67 in transfected cells and tumors absent or enriched in the transferrin receptor. J Nucl Med 1998; 39: 1405-1411.
16. Toth I, Yuan L, Rogers JT, Boyce H, Bridges KR. Hypoxia alters iron-regulatory protein-1 binding capacity and modulates cellular iron homeostasis in human hepatoma and erythroleukemia cells. J Biol Chem 1999; 274: 4467-4473.
17. Tacchin L, Bianchi L, Bernelli-Zazzera A, Cairo G. Transferrin receptor induction by hypoxia. J Biol Chem 1999; 274: 24142-24146.
18. Bianchi L, Tacchini L, Cairo G. HIF-mediated activation of transferrin receptor gene transcription by iron chelation. Nucleic Acids Res 1999; 27: 4223-4227.
19. Tacchini L, Poli DF, Bernelli-Zazzera A, Cairo G. Transferrin receptor gene expression and transferrin-bound iron uptake are increased during postischemic rat liver reperfusion. Hepatology 2002; 36: 103-111.
20. Barabas K, Faulk WP. Transferrin receptors associate with drug resistance in cancer cells. Biochem Biophys Res Commun 1993; 197: 702-708.
21. Fritzer M, Szekeres T, Szuts V, Jarayam HN, Goldenberg H. Cytotoxic effects of a doxorubicin-transferrin conjugate in multidrug-resistant KB cells. Biochem Pharmacol 1996; 51: 489-493.
22. Sadava D, Phillips T, Lin C, Kane SE. Transferrin overcomes drug resistance to artemisinin in human small-cell lung carcinoma cells. Cancer Lett 2002; 179: 151-156.
23. 99mTc-HL91. Eur J Nucl Med 2002; 29: 1006-1111.
24. Cook GJ, Houston S, Barrington SF, Fogelman I. Technetium-99m-labeled HL91 to identify tumor hypoxia: correlation with fluorine-18-FDG. J Nucl Med 1998; 39: 99-103.
25. Tatsumi M, Yutani K, Kusuoka H, Nishimura T. Technetium-99m HL91 uptake as a tumour hypoxia marker: relationship to tumour blood flow. Eur J Nucl Med 1999; 26: 91-94.
26. 99mTc-HL91, a putative hypoxic tracer, to detection of tumor hypoxia. J Nucl Med 1999; 40: 854-861.
27. 99mTc]HL-91: correlation with microelectrode measurements. J Nucl Med 2001; 42: 337-344.
28. Tsan M-F, Scheffel U, Tzen K-Y, Camargo EE. Factors affecting the binding of gallium-67 in serum. Int J Nucl Med Biol 1980; 7: 270-273.
29. 67Ga incorporation into human granulocytes. Cancer Res 1979; 39: 4971-4974.
30. 67Ga scintigraphy after one cycle of chemotherapy. Radiology 1999; 210: 487-491.
31. Delcambre C, Reman O, Henry-Amar M, Peny AM, Macro M, Cheze S, et al. Clinical relevance of gallium-67 scintigraphy in lymphoma before and after therapy. Eur J Nucl Med 2000; 27: 176-184.
32. 67Ga scintigraphy. Radiology 2000; 214: 253-257.
33. Israel O, Mor M, Epelbaum R, Frenkel A, Haim N, Dann EJ, et al. Clinical pretreatment risk factors and Ga-67 scintigraphy early during treatment for prediction of outcome of patients with aggressive non-Hodgkin lymphoma. Cancer 2002; 94: 873-878.
34. Brenot-Rossi I, Bouabdallah R, Di Stefano D, Bardou VJ, Stoppa AM, Camerlo J, et al. Hodgkin's disease: prognostic role of gallium scintigraphy after chemotherapy. Eur J Nucl Med 2001; 28: 1482-1488.
35. 67Ga scintigraphy and CT for prediction of outcome after treatment. J Nucl Med 2002; 43: 1295-1303.
36. Clavo AC, Brown RS, Wahl RL. Fluorodeoxyglucose uptake in human cancer cell lines is increased by hypoxia. J Nucl Med 1995; 36: 1625-1632.
37. Del Vecchio S, Ciarmiello A, Salvatore M. Scintigraphic detection of multidrug resistance in cancer. Cancer Biother Radiopharm 2000; 15: 327-337.
38. Ballinger JR. Imaging multidrug resistance with radiolabeled substrates for P-glycoprotein and multidrug resistance protein. Cancer Biother Radiopharm 2001; 16: 1-7.